I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-12. (Canceled)

13. (Currently Amended) A method of manufacturing a composition comprised of effector T lymphocytes generated by:

a. vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant comprising GM-CSF;

b. removing primed peripheral blood T lymphoctyes from the patient;

c. stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro; and

d. stimulating the effector T lymphocytes to proliferate in vitro.

14. (Cancelled).

15. (Original) The method in claim 13 wherein the removal step is performed by leukapheresis.

16. (Original) The method in claim 13 wherein the differentiation step is performed using anti-CD3.

17. (Original) The method in claim 13 wherein the proliferating step is performed using IL-2.

18-22. (Canceled)

23. (Previously presented) The method in claim 13 wherein said patient's own malignancy comprises breast cancer.

24. (Previously presented) The method in claim 13 wherein said patient's own malignancy comprises astrocytoma.

25. (Previously presented) The method in claim 13 wherein said patient is vaccinated at multiple body sites.

26. (Previously presented) The method in claim 13 wherein the patient is vaccinated with at least 5×10^6 malignant cells.

27. (Previously presented) The method in claim 13 wherein said patient is vaccinated at the time of initial diagnosis.

28. (Previously presented) The method in claim 13 further comprising the step of irradiating said patient's malignancy prior to said vaccination step.

29. (New) The method in claim 13 wherein the removal step is performed by leukapheresis, the differentiation step is performed using anti-CD3, and the proliferating step is performed using IL-2.

30. (New) The method in claim 13 wherein the removal step is performed by leukapheresis, and the differentiation step is performed using anti-CD3.